Collegium Pharmaceutical (COLL) Long-Term Deferred Tax: 2021-2025
Historic Long-Term Deferred Tax for Collegium Pharmaceutical (COLL) over the last 5 years, with Sep 2025 value amounting to $102.5 million.
- Collegium Pharmaceutical's Long-Term Deferred Tax rose 41.33% to $102.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.5 million, marking a year-over-year increase of 41.33%. This contributed to the annual value of $98.0 million for FY2024, which is 273.33% up from last year.
- As of Q3 2025, Collegium Pharmaceutical's Long-Term Deferred Tax stood at $102.5 million, which was up 11.43% from $92.0 million recorded in Q2 2025.
- Over the past 5 years, Collegium Pharmaceutical's Long-Term Deferred Tax peaked at $102.5 million during Q3 2025, and registered a low of $23.9 million during Q4 2022.
- Its 3-year average for Long-Term Deferred Tax is $56.6 million, with a median of $34.2 million in 2024.
- Its Long-Term Deferred Tax has fluctuated over the past 5 years, first plummeted by 69.31% in 2022, then skyrocketed by 273.33% in 2024.
- Collegium Pharmaceutical's Long-Term Deferred Tax (Quarterly) stood at $78.0 million in 2021, then tumbled by 69.31% to $23.9 million in 2022, then climbed by 9.64% to $26.3 million in 2023, then soared by 273.33% to $98.0 million in 2024, then skyrocketed by 41.33% to $102.5 million in 2025.
- Its Long-Term Deferred Tax stands at $102.5 million for Q3 2025, versus $92.0 million for Q2 2025 and $91.7 million for Q1 2025.